AI Analysis
AI-generated analysis. Always verify with the original filing.
Novo Nordisk A/S held its Annual General Meeting on March 26, 2026, approving the 2025 Annual Report, a final dividend of DKK 7.95 per A and B share (total DKK 11.70 including interim), Board elections and re-elections, remuneration approvals, share repurchase and capital increase authorizations, and a change in general meeting location.
Key Takeaways
1Final dividend for 2025: DKK 7.95 per Novo Nordisk A and B share of DKK 0.10, payable March 2026; total dividend DKK 11.70
2Re-election of Lars Rebien Sørensen as Board chair and Cees de Jong as vice chair
3Election of new Board members: Helena Saxon, Jan van de Winkel, Ramona Sequeira
4Board authorization to repurchase up to 10% of share capital until AGM 2027
5Extension of share capital increase authorization to DKK 44,650,000 until April 1, 2028
6Change in articles: general meetings to be held in Region of Eastern Denmark